A Foamix ac­ne drug PhI­II bombs, send­ing shares in­to a tail­spin

While Al­ler­gan was pulling in­to the fi­nal reg­u­la­to­ry lap this morn­ing with its ex­per­i­men­tal ac­ne drug, ri­vals at Foamix tripped over a Phase III hur­dle for an­oth­er con­tes­tant in the field.

Shares of Foamix Phar­ma­ceu­ti­cals were crushed in pre-mar­ket trad­ing on Mon­day af­ter the biotech re­port­ed that its ac­ne drug came up with a split de­ci­sion in two Phase III stud­ies.

FMX101, which was used to sell its lack­lus­ter 2014 IPO, hit the co-pri­maries for a re­duc­tion in le­sions and an IGA score for suc­cess in tri­al 05. Tri­al 04, though, proved a flop. And in­vestors were rout­ed on the mixed re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER